203 related articles for article (PubMed ID: 31785928)
1. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
[TBL] [Abstract][Full Text] [Related]
2. Secreted calreticulin mutants subvert anticancer immunosurveillance.
Liu P; Zhao L; Kroemer G; Kepp O
Oncoimmunology; 2020; 9(1):1708126. PubMed ID: 32002304
[TBL] [Abstract][Full Text] [Related]
3. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
Kepp O; Liu P; Zhao L; Plo I; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
5. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
Cimen Bozkus C; Roudko V; Finnigan JP; Mascarenhas J; Hoffman R; Iancu-Rubin C; Bhardwaj N
Cancer Discov; 2019 Sep; 9(9):1192-1207. PubMed ID: 31266769
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin and cancer.
Fucikova J; Spisek R; Kroemer G; Galluzzi L
Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
[TBL] [Abstract][Full Text] [Related]
8. Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.
Shide K; Kameda T; Kamiunten A; Oji A; Ozono Y; Sekine M; Honda A; Kitanaka A; Akizuki K; Tahira Y; Nakamura K; Hidaka T; Kubuki Y; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Ikawa M; Shimoda K
Blood Cancer J; 2019 Mar; 9(4):42. PubMed ID: 30926777
[TBL] [Abstract][Full Text] [Related]
9. Calreticulin mutations affect its chaperone function and perturb the glycoproteome.
Schürch PM; Malinovska L; Hleihil M; Losa M; Hofstetter MC; Wildschut MHE; Lysenko V; Lakkaraju AKK; Maat CA; Benke D; Aguzzi A; Wollscheid B; Picotti P; Theocharides APA
Cell Rep; 2022 Nov; 41(8):111689. PubMed ID: 36417879
[TBL] [Abstract][Full Text] [Related]
10. Impact of Calreticulin and Its Mutants on Endoplasmic Reticulum Function in Health and Disease.
Arshad N; Cresswell P
Prog Mol Subcell Biol; 2021; 59():163-180. PubMed ID: 34050866
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
12. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
13. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
15. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes.
Schcolnik-Cabrera A; Oldak B; Juárez M; Cruz-Rivera M; Flisser A; Mendlovic F
Apoptosis; 2019 Apr; 24(3-4):245-255. PubMed ID: 30929105
[TBL] [Abstract][Full Text] [Related]
17. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Holmström MO; Martinenaite E; Ahmad SM; Met Ö; Friese C; Kjær L; Riley CH; Thor Straten P; Svane IM; Hasselbalch HC; Andersen MH
Leukemia; 2018 Feb; 32(2):429-437. PubMed ID: 28676668
[TBL] [Abstract][Full Text] [Related]
18. Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.
Balliu M; Calabresi L; Bartalucci N; Romagnoli S; Maggi L; Manfredini R; Lulli M; Guglielmelli P; Vannucchi AM
Blood Adv; 2021 Apr; 5(8):2184-2195. PubMed ID: 33890979
[TBL] [Abstract][Full Text] [Related]
19. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
20. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]